SK Biopharmaceuticals agreed to acquire global commercialization rights to Biohaven’s opakalim (BHV-7000) in an up-to-$795 million deal, extending SK Life Science’s epilepsy franchise alongside XCOPRI (cenobamate). SK will pay $350 million at closing with $50 million due in 2027, plus additional consideration tied to milestones. Opakalim is a selective Kv7.2/7.3 potassium channel activator in Phase II/III development (NCT06132893) for focal epilepsy, with Biohaven positioning it as a once-daily oral option designed to avoid titration and sedation issues tied to older antiseizure therapies. The agreement is structured to accelerate launch execution by leveraging SK’s existing neurology field force and payer access infrastructure. Closing is subject to standard conditions, including US Hart-Scott-Rodino review.